Declining Onchocerca volvulus transmission despite limited ivermectin delivery in the Kakoi–Koda focus, Ituri, Democratic Republic of the Congo: An epidemiological, entomological and landscape evidence synthesis
Authors: Luís-Jorge Amaral, Tony Ukety, Jules Upenjirwoth, Deogratias Ucima Wonya’Rossi, Michel Ndahura Mandro, Françoise Nyisi, Pascal Adroba, Wilma A. Stolk, Joseph N. Siewe Fodjo, María-Gloria Basáñez, Anne Laudisoit, Robert Colebunders, Eva Clark, Robert Adamu SHEY, Eva Clark, Robert Adamu SHEY, Eva Clark, Robert Adamu SHEY
Published: 2026
ABSTRACT
BackgroundThe Kakoi–Koda focus in Ituri Province was historically hyperendemic for onchocerciasis, yet screening for a recent trial suggested a marked decline, including in Logo Health Zone, which had never received routine ivermectin. We explored whether this decline extended across the focus and how infection indicators corresponded spatially with ivermectin delivery, entomological observations and deforestation.MethodologyWe conducted a scoping evidence synthesis of epidemiological, programmatic, entomological and geospatial sources. Against a 2003 nodule-mapping baseline, change was assessed from repeated cross-sectional moxidectin trial screenings in 2010–11 and 2021–2023, which applied the same four-skin-snip protocol to community-recruited residents aged ≥12 years. Anti-Ov16 serology (2015–21), two-skin-snip surveys (2015/17), exploratory blackfly observations (2009–18) and remotely sensed tree-cover loss (2001–24) provided further contextual evidence.Principal findingsBetween the two trial screenings, microfilarial prevalence significantly declined from 79.0% to 9.0% (Draju) and 68.9% to 8.6% (Kanga) in Logo, similar to declines observed in villages of Nyarambe Health Zone (72.2% to 2.9%), which received routine ivermectin for lymphatic filariasis. Mean infection intensity mirrored this pattern, from 17-26 to 1 microfilariae per milligram of skin in Logo, and 11 to 0.4 in Nyarambe. Seroprevalence in children aged 3–10 years from 2016 onward was low (0–5%), geographically circumscribed and broadly concordant with the skin-snip spatial pattern. Opportunistic blackfly collections and breeding-site prospections detected Simulium dentulosum and S. vorax as the current anthropophagic species, with no evidence of S. neavei after 2009. Extensive dense forest loss (75–90% in historically hyperendemic Logo) and canopy opening are consistent with a shift from crab-associated S. neavei habitats towards more open-habitat vectors, providing a plausible ecological mechanism.SignificanceParasitological, serological, entomological and geospatial evidence consistently indicates substantial declines in O. volvulus infection indicators across Kakoi-Koda, compatible with reduced transmission. Residual positive indicators were spatially circumscribed, including in Logo where no routine ivermectin was delivered. Whether the current simuliid species can sustain transmission above elimination thresholds remains uncertain. Standardised, representative surveys in the Muda/Kuda and Lebu River basins are warranted to guide decisions on starting and stopping ivermectin delivery.
1. Introduction
Onchocerciasis is a neglected tropical disease (NTD) targeted for interruption (elimination) of transmission by the World Health Organization [1]. The causative agent, the filarial nematode worm Onchocerca volvulus, is transmitted among humans by female Simulium blackfly bites [1]. More than 99% of infections occur in sub-Saharan Africa [2], where control relies mainly on community-directed treatment with ivermectin (CDTI) delivered once or twice a year to populations at risk [3]. Ivermectin is primarily microfilaricidal (kills microfilariae, the embryonic stage of the parasite) and transiently suppresses embryogenesis in adult female worms [3]. In addition, a moderate permanent sterilising effect has also been described [4]. Although macrofilaricidal activity (killing of adult worms) has been reported and quantified [5,6], adult worms can persist for many years despite periodic treatment [3,7]. Therefore, CDTI must be regularly administered for prolonged periods, accounting for both the long reproductive lifespan of adult worms [8] and the possibility of continued reinfection in areas of intense transmission. Historically, vector control (against blackflies) has also been implemented, mainly in West Africa [9,10]. The disease is characterised by a range of cutaneous and ocular clinical manifestations (including irreversible blindness), and is epidemiologically associated with neurological sequelae within the spectrum of onchocerciasis-associated-epilepsy (OAE) [11].
The Democratic Republic of the Congo contains numerous O. volvulus foci associated with fast-flowing rivers that harbour blackfly breeding sites [12–15]. The African Programme for Onchocerciasis Control (APOC, 1995–2015) supported the scale-up of CDTI in those areas where onchocerciasis was considered to be a public health problem (i.e., where the baseline infection level was at least mesoendemic) [16], leading to 22 CDTI projects in DRC by 2012 [17–20]. However, geographical and therapeutic coverage remained inconsistent due to insecurity, programme boundaries and reporting constraints [21].
The Kakoi-Koda onchocerciasis focus lies on the steep Ituri highland slopes above Lake Albert [18]. Rapid epidemiological mapping of onchocerciasis (REMO) surveys conducted in 2003 identified several highly endemic villages of the focus, within the Angumu, Logo and Nyarambe Health Zones (HZs) [22,23]. Routine onchocerciasis CDTI was subsequently implemented in Angumu HZ, whereas Logo and Nyarambe HZs were excluded as most of their communities were considered to have low onchocerciasis endemicity [19,20,24]. Nyarambe later received mass drug administration of ivermectin and albendazole through the lymphatic-filariasis control programme [21]. Community screening in Logo and Nyarambe HZs for clinical trials of moxidectin versus ivermectin in 2010–2011 and 2021–2023 documented a marked decline in O. volvulus microfilarial prevalence and infection intensity between trials [22].
The microfilarial prevalence decline observed in Logo, in the absence of CDTI, was unexpected and raised the question about how it related to the longer-term epidemiological history and wider spatial context of the Kakoi–Koda focus. In particular, the geographical extent of the decline, the location of possible residual transmission signals and their spatial correspondence with heterogeneous ivermectin delivery, entomological observations over time and landscape change remained to be elucidated. We therefore synthesised the available epidemiological, serological, programmatic, entomological and geospatial evidence in the last 25 years, including forest-cover change around streams, to describe changes in transmission indicators across the focus and to place the trial-screening findings within their broader eco-epidemiological context. While Ngave et al. (2026) describe the individual-level comparison of the two trial-screening periods [22], the present manuscript addresses the wider spatial and temporal evidence base. Our objectives were to identify temporal trends in infection indicators, characterise ivermectin delivery and entomological observations, and assess their descriptive spatial correspondence with tree-cover loss.
2. Methods
2.1 Ethical statement
This study was conducted under approvals from the Ethics Committee of the University of Antwerp (B300201525249; B300201733350), the Ethics Committee of Ngaliema Hospital, Kinshasa (P: Eth/436/2015) and the Ethics Committee of the University of Kinshasa School of Public Health (ESP/CE/013/2018). Permissions were also obtained from provincial and health-zone authorities. The blackfly collections reported here were conducted under a previously published protocol [18] and approved by the ethics described above. Blackfly collectors were adults (≥18 years) from local communities who provided written informed consent and were provided with ivermectin prior to participating in the collections.
2.2 Study setting and periods
The demographics of the Kakoi-Koda focus are presented according to the current territorial and administrative division of health, namely territories, health zones (HZs) and health areas (HAs). The study area is located in the Ituri Province of the DRC (Mahagi and Djugu territories), in the five HZs comprising the Kakoi-Koda onchocerciasis focus, namely Angumu, Logo, Mahagi, Nyarambe and Rethy (Fig 1). The focus occupies approximately 70,000 hectares along the northeastern Ituri Highlands escarpment from the Blue Mountains near Mount Aboro down towards Lake Albert [18]. Elevation ranges from roughly 620–2,450 metres above sea level. The focus lies largely between the Kakoi and Koda rivers, with the Kuda, Lebu and Awo rivers crossing it (Fig 2) [18].
Location of the study areas in the Democratic Republic of the Congo (DRC).
(A) Position of the DRC (orange) within Africa. (B) Ituri Province (dark grey) highlighted within the DRC. (C) Map showing the Health Zones of Angumu (green), Logo (blue), Mahagi (orange), Nyarambe (red) and Rethy (pink) in East Ituri Province, with their respective Health Areas delineated (light grey). The map was produced in ArcGIS Pro (Esri, Redlands, CA, USA) using publicly available spatial datasets (GRID3 COD – Health Areas v5.0 https://doi.org/10.7916/nnew-da26 [25], and GRID3 COD – Health Zones v5.0 https://doi.org/10.7916/d8rn-6e24 [26]).
Nodule prevalence in the Kakoi–Koda onchocerciasis focus assessed in 2003 by Rapid Epidemiological Mapping of Onchocerciasis (REMO)/Rapid Epidemiological Assessment (REA) [23].
Clusters of ≥20% nodule prevalence delineate the focus in orange (mesoendemicity) and red (hyperendemicity). Areas with <20% nodule prevalence are shown as yellow (hypoendemicity) and green (non-endemic/sporadic endemicity). Only river basins pertinent to delineating the focus and major rivers are displayed (blue/teal, with names in black bold). Health zones comprising the focus are colour-shaded as follows: Angumu (pink), Logo (light pink/peach), Mahagi (purple/lilac), Nyarambe (light blue), Rethy (brown), with health areas outlined (thin black contours) with their name labels (haloed in white). The map was produced in ArcGIS Pro (Esri, Redlands, CA, USA) using publicly available spatial datasets (GRID3 COD – Health Areas v5.0 https://doi.org/10.7916/nnew-da26 [25] and GRID3 COD – Health Zones v5.0 https://doi.org/10.7916/d8rn-6e24 [26]). River and stream networks were derived from OpenStreetMap (https://www.openstreetmap.org) [43] and adjusted using ground-truth waypoints.
Current land cover on the highlands is predominantly savannah with fragmented primary and secondary forest blocks/patches, with forest more extensive to the west and a forest-savannah mosaic extending eastward [27]. The climate is humid tropical with weakly bimodal seasons (with some variation consisting of the main rains around July–October, main dry season November–March, minor rains in April–May and minor dry season in June) [18,24] and approximately 1,400 millimetres of mean annual precipitation [28].
2.3 Evidence synthesis
We conducted a scoping evidence synthesis of onchocerciasis and Simulium vectors in the Kakoi-Koda focus from 1980 to 31 July 2025, informed by PRISMA-ScR guidance (PRISMA extension for scoping reviews, as detailed by Tricco et al. 2018 [29]). We searched PubMed, Google (Scholar) and the World Health Organization’s Institutional Repository for Information Sharing (WHO IRIS) using combinations of: “onchocerciasis”, “Simulium”, “blackfly”, “Kakoi”, “Koda” and “Ituri” and their French equivalents (“onchocercose”, “simulie” and “mouche noire”) in titles, abstracts or mentions in the text. The use of “Ituri” as a required term ensured the retrieval of studies from both before and after the area’s official designation as Ituri Province (formerly known as Ituri District within Orientale Province). In addition to electronic searches, we reviewed: (1) programme documents from the DRC National Onchocerciasis Elimination Programme, (2) data from the Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN) portal for DRC [21], (3) reports and protocols generated within the NSETHIO research programme [30–32], and (4) reference lists from relevant review articles for additional sources. This approach allowed us to capture both peer-reviewed publications and grey literature (reports) relevant to the context of the Kakoi-Koda focus.
The inclusion criteria included studies or reports with information on: (1) programmatic data (i.e., CDTI distribution and coverage), (2) onchocerciasis epidemiology (i.e., nodule palpation, anti-Ov16 serological and skin-snip surveys), and/or (3) entomology (i.e., human landing catches, blackfly testing for O. volvulus infection/infectivity, and breeding site prospections) from at least one of the five HZs of the Kakoi-Koda focus (as illustrated in Fig 1). Exclusion criteria comprised studies and documents without geographical relevance to the focus or lacking extractable outcomes. Titles, abstracts and study reports were screened, and relevant data items were extracted by LJA (location, year, population, numbers examined, diagnostic method, key epidemiological, entomological and programmatic indicators, and vector species), summarised in Results subsection 3.1, and the full extraction is provided in the (Supplementary) S1 Data. Discrepancies were resolved by discussion with the remaining co-authors.
2.4 Clinical trial contexts and repeated screening comparison
Four trials delivered moxidectin or ivermectin to recruited participants in the focus: the Phase III moxidectin trial 3110A1-3000 (2010–2011 [33,34]), a proof-of-concept ivermectin trial in persons with epilepsy (2017–2018 [35,36]), and the Phase IIIb moxidectin trials MDGH-MOX-3002 (2021–2023 [22,37]) and MDGH-MOX-3001 (2021–2026, ongoing, [22,38]). The three moxidectin trials recruited community residents aged ≥12 years and used four iliac-crest skin snips per person during screening [22,33,39,40]. Although the denominator for microfilarial prevalence comprised all screened residents with valid microscopy results, trial enrolment required participants to meet a specified infection threshold. The two later moxidectin trials expanded screening and relaxed enrolment criterion to positivity in at least one skin snip, because few residents met the earlier 2010–2011 criterion of ≥10 microfilariae per milligram of skin. Our repeated cross-sectional comparison is restricted to pretreatment screening outcomes, all measured using the same four-skin-snip protocol. The individual-level, village-adjusted logistic regression comparing the two screening periods is reported in the dedicated 2026 article [22]. Therefore, the present synthesis reports HA-level estimates descriptively and does not duplicate that analysis. As the ivermectin trial recruited only persons with epilepsy and used two skin snips per participant, its screening data were excluded from the repeated cross-sectional comparison.
2.5 Geospatial analysis of tree cover and deforestation
We quantified forest cover change using the Global Forest Change dataset by Hansen et al. (30-metre resolution of per cent tree cover in 2000 and annual tree loss from 2001 to 2024) [41,42]. Administrative boundaries for HZs and HAs in the focus were obtained from GRID3 COD – Health Areas v5.0 (https://doi.org/10.7916/nnew-da26) [25] and GRID3 COD – Health Zones v5.0 (https://doi.org/10.7916/d8rn-6e24) [26], respectively. Rivers and streams networks were extracted from OpenStreetMap to visualise waterways in the study area (https://www.openstreetmap.org) [43] and corrected based on ground-truth waypoints.
For the present geospatial analyses, the Hansen rasters were spatially restricted to the five HZs of the Kakoi-Koda focus and all layers were re-projected to a common coordinate system (WGS 1984 UTM Zone 36N). Forest in 2000 was defined as pixels with tree cover ≥30% (as used by Hansen et al. [41] and the definition followed by the DRC [44]), and forest loss as pixels that were forest in 2000 and had a non-zero loss year (2001–2024). Using zonal tabulations, we calculated for each HA the area of forest in 2000 and the area of that forest that was subsequently lost, and expressed deforestation as the percentage of 2000 forest cover lost by 2024. These HA-level estimates were then mapped, as well as summarised by HZ. We repeated this analysis with the definition of “dense forests” as pixels with tree cover ≥70% [45] to better capture closed-canopy habitats likely to be relevant for Simulium neavei [46]. Spatial analyses and map visualisations were performed in ArcGIS Pro (Esri, Redlands, CA, USA) and ArcGIS Online.
2.6 Interactive web map and data availability
To complement the static figures, we assembled an interactive web map (ArcGIS Online) that overlays epidemiological and entomological observations with geospatial context by survey year and data type. In parallel, all epidemiological, entomological, programmatic and geospatial inputs (including NSETHIO survey data not previously reported) were harmonised for the synthesis into a single master dataset accompanying this article (S1 Data). The dataset includes standardised variables, harmonised geographical identifiers, and documentation of data provenance and processing steps.
The web map includes: 1) REMO nodule surveys; 2) anti-Ov16 serological surveys (children; adults; combined); 3) skin-snip microscopy surveys (population; adolescents only; adolescents and adults); 4) freshwater-crab trapping data for S. neavei-associated breeding; 5) breeding-site inspections for blackfly larvae; and 6) human-biting blackfly data using human landing catch (HLC). Additionally, map layers include health-zone/health-area boundaries, rivers/streams, and annual tree-cover loss since 2000. Each layer has metadata describing source, dates, methods and any harmonisation applied. The ArcGIS interactive item is publicly accessible online (https://arcg.is/1PDyO0), and a README file is available in (Supplementary) Text A in S1 Appendix. To protect privacy, all data are aggregated at the village level and contain no personal identifiers.
2.7 Statistical analysis
We analysed data on programmatic treatment coverage, O. volvulus epidemiology (REMO nodule prevalence categories, anti-Ov16 seropositivity and skin snip (microfilarial) prevalence) and entomology (simuliid larval breeding site prospections, and HLC data). Non-normally distributed (non-Gaussian) continuous variables were summarised as medians with interquartile ranges (IQRs, 1st quartile to 3rd quartile). Categorical data are presented as counts and percentages, and, where relevant, 95% confidence intervals (95% CIs) were computed using the Wilson score method with continuity correction [47,48].
Because study designs, diagnostics, age groups and protocols varied across data sources, temporal comparisons across heterogeneous contextual sources were descriptive, and formal analyses were limited to the repeated trial-screening comparison and the within-dataset analyses described below. We harmonised metrics by data type and protocol, year data were collected, GPS coordinates (i.e., by HA and HZ for epidemiology data; river basins for entomology; village level for the interactive web map) and age strata (epidemiology: all ages ≥3 years for population prevalence data; children and adolescents as indicators of recent transmission). GPS coordinates were converted into decimal degrees and mapped in ArcGIS.
To characterise age- and sex-specific cumulative exposure to O. volvulus, we used data from the cross-sectional community anti-Ov16 rapid diagnostic test (RDT) survey in Logo HZ in 2016, identified in the evidence synthesis, restricted to residents aged ≥3 years with valid serology (n = 921). We focused on this community-based dataset because the remaining serology datasets were not population-representative. Ages were grouped into 3–6, 7–10, 11–20, 21–30, 31–40, 41–50 and ≥51 years to ensure sufficient sample sizes per band. For each age group and sex, we estimated anti-Ov16 seroprevalence with 95% CIs using the Wilson score method with continuity correction and displayed these estimates in an age- and sex-specific seroprevalence plot. We fitted a logistic regression model with age, sex and their interaction, adjusting for health area, to assess age and sex differences in cumulative exposure.
For person-level paired comparisons of skin-snip microscopy and field anti-Ov16 RDT among children aged 3–10 years (indicative of ongoing transmission), we reported per cent agreement and Cohen’s kappa (κ) with asymptotic 95% CIs. Marginal homogeneity was assessed using McNemar’s test with mid-p two-sided p-values due to the small number of discordant pairs [49]. Skin-snip results were taken as a reference to estimate the sensitivity and specificity of anti-Ov16 RDT in the field, with exact (Clopper-Pearson) 95% CIs given the small sample size and sparse discordant data. Analyses were performed in R (version 4.4.1) using base functions and the packages DescTools (κ, CIs) [50] and epiR (diagnostic accuracy) [51].
3. Results
3.1 Evidence base and data coverage
We assembled epidemiological, entomological and control programme data for the Kakoi-Koda focus from 1980 to 2025. Table 1 summarises designs, populations, procedures, metrics, years, areas and key limitations for each data stream. Epidemiological sources included REMO nodule palpation, anti-Ov16 serology from community, case-control and cohort surveys investigating OAE, and community and study-based skin-snip surveys (including screening datasets from the 2010–2011 and 2021–2023 moxidectin clinical trials). Entomology encompassed targeted inspections of breeding sites and freshwater crabs, (informal) “spot checks” of human-biting blackfly species by HLC and use of genus-specific mitochondrial 16S rDNA gene and species-specific NADH dehydrogenase subunit 5 (ND5) gene polymerase chain reaction (PCR) for the detection of O. volvulus DNA in flies’ heads (infectivity prevalence) or heads and bodies (infection prevalence) in blackfly samples. Programme documents provided contextual information on ivermectin distribution history (i.e., geographical and therapeutic coverage) by HZ and calendar year. The next subsections detail (3.1.1) CDTI delivery histories by HZ and HA, (3.1.2) temporal patterns in infection indicators, and (3.1.3) vector species and transmission ecology. HA-level estimates with denominators and 95% confidence intervals for every data stream are tabulated in Table A–E in S1 Appendix, and the individual-level records underlying them are provided in S1 Data.
10.1371/journal.pntd.0014164.t001Table 1Epidemiological and entomological data sources and methods in the Kakoi–Koda onchocerciasis focus, Ituri Province, DRC.Data designPurpose / IndicatorTarget population / SamplingMethodsMetrics reportedCoverage sources (years: area [source of data])Key limitations / Sources of bias CDTI programme coverage Geographical and therapeutic coverage of ivermectin distribution; rounds per yearCoverage of the total populationData aggregated by community, HA or HZCommunity-directed treatment registers were collated at the HZ levelCommunity-based and case-control surveys were used as supplementary checks where availableGeographical coverage: proportion of targeted communities treated by HA or HZTherapeutic coverage: number treated in the total population (all ages) of targeted areaDelivery pattern: number of ivermectin rounds per year; programme platform1) 2014–2023 ESPEN HZ-level coverage (ivermectin for onchocerciasis and/or lymphatic filariasis) [21]; 2) & 3) August and October 2015 epilepsy case-control (persons with epilepsy and community controls) coverages: Logo HZ (Draju HA) and Rethy HZ (Lokpa HA) reported ivermectin intake used to confirm occurrence/level of ivermectin delivery in 2014 [52–54]; 4) 2021 children (aged 5–9 years) community survey: Nyarambe HZ (Kpanyi HA) 2020 coverage check (published with this manuscripta); 5) 2021–2023 moxidectin trial: Logo HZ (Draju, Kanga, Thedeja HAs) and Nyarambe HZ (Kpanyi HA)Administrative denominators uncertain (migration, insecurity, underestimated census); incomplete or delayed reportingShort distribution windows; limited independent verification (lack of coverage survey data)Interruptions to treatment due to insecurity and the COVID-19 pandemic Nodule palpation surveys REMO/REA: rapid endemicity classification for programme control decisionsEpilepsy cohort nodule palpation: presence of palpable nodules within a defined epilepsy cohort; contextualises onchocerciasis exposure in persons with epilepsyREMO/REA: 30–50 adults, typically men aged ≥20 years with ≥10 years residence per village or sentinel site [20]Epilepsy cohort: all consenting persons with epilepsy (both sexes, all ages) enrolled in the cohort [55]Standardised palpation of common body sites (e.g., bony prominences) for onchocercal subcutaneous nodules by trained examiners [20]REMO/REA: nodules per person and prevalence (%) in adults; used to classify endemicity (e.g., < 20% hypoendemic, 20–39.9% mesoendemic, ≥ 40% hyperendemic) [17]Epilepsy cohort: nodule prevalence (%) within the cohort [55]REMO/REA: 1) 2003: Angumu HZ (Aree, Bessi, Dabu, Langa, Musongwa HAs), Logo HZ (Draju, Kanga, Thedeja HAs), Mahagi HZ, Nyarambe HZ (Afoyo, Nyalebbe, Pundiga HAs), and Rethy HZ (Rassia HA) [23]; 2009: Logo HZ (Otha HA) [56]; 3) September 2015: Logo HZ (Draju HA) and Rethy HZ (Lokpa, Rassia HAs) [52]; 4) November 2017: Logo HZ (Draju, Kanga, Walla HAs) (nodule findings published with this manuscript, collected during study [57])Epilepsy cohort: 5) October 2017: Logo HZ (Draju HA) [55]Palpable nodules are used to indicate the presence of adult worms; however, their diagnostic value is poorer in low transmission (hypoendemic) areas [19]Focal transmission may be missed; limited sensitivity under changes in transmission conditions [58]REMO/REA: standardised adult-only, male-predominant samples improve comparability with (and conversion into) microfilarial prevalence but may not be population-representativeEpilepsy cohort: findings apply to persons with epilepsy only Anti-Ov16 serology All-age surveys: exposure to O. volvulus infection (cannot distinguish between past and current)Child surveys (3–10 years): Indicator of ongoing transmissionAll-age surveys: Resident population aged ≥3 years (community or study-specific samples)Child surveys: community samples of children aged 3–10 yearsSD Bioline Onchocerciasis Ov16 IgG4 rapid diagnostic test (RDT) conducted in the field on capillary blood (finger-prick) samples [54]; results read after 20 minutes [59]Anti-Ov16 IgG4 ELISA in the laboratory [22]Anti-Ov16 seroprevalence (%) in the community (all-age) or among children aged 3–10 yearsAll-age surveys: 1) 2015 community survey (ESPEN): Angumu, Mahagi, Nyarambe and Rethy HZs [22]; 2) October 2015 epilepsy case-control study: Logo HZ (Draju HA) and Rethy (Lokpa, Kpandroma, Rassia HAs) [52,53]; 3) August 2016 community survey: Logo HZ (Draju, Kanga, Ulyeko HAs) [54]; 4) October 2017 epilepsy cohort study: Logo HZ (Draju HA) [55]Child surveys: 5) 2018 community survey: Logo HZ (Kanga, Walla HAs) (published with this manuscripta); 6) February 2021 community survey: Nyarambe HZ (Kpanyi HA) (published with this manuscripta)RDT and ELISA have limited accuracy (sensitivity/specificity); cannot time infection or separate past from current [58]; potential reader variability (e.g., faint bands) in field RDTs [60]Some sampling frames are not fully representative of the population (e.g., epilepsy case-control/cohort design), but they still inform on onchocerciasis exposure and recent transmission, especially in young children Skin-snip microscopy surveys Current O. volvulus infection (prevalence and intensity)Moxidectin trials: residents aged ≥12 years; 4 skin snips per person [22]Other surveys: residents aged ≥5 years; 2 skin snips per person (community-based and epilepsy studies) [55]Iliac-crest snips with a 2-millimetre Holth punch; 8–24 hours incubation in isotonic saline solution in flat-bottom microtitre plates; emerged microfilariae counted by inverted microscopy [22,55]; results expressed as microfilariae presence and number per skin snipMicrofilaria-positive prevalence (%) and average microfilariae counts per person to calculate infection intensity in the population (moxidectin trials: geometric mean number of microfilariae per milligram of skin; other surveys: geometric mean number of microfilariae per skin snip)Moxidectin trials: 1) 2010–11: Logo HZ (Ambere, Buu, Draju, Jupahoy, Kanga, Ndrele, Ulyeko, Walla HAs) and Nyarambe HZ (Kpanyi HA) [39]; 2) 2021–2023: Logo HZ (Draju, Kanga, Thedeja HAs) and Nyarambe HZ (Kpanyi HA) [22]Other surveys: 3) 2015 community survey (ESPEN): Angumu, Mahagi, Nyarambe and Rethy HZs [22]; 4) August 2015 epilepsy case-control study: Logo HZ (Draju HA) and Rethy HZ (Lokpa HA) [54]; 5) October 2015 epilepsy case-control study: Logo HZ (Draju HA) and Rethy HZ (Lokpa, Rassia HAs) [52,53]; 6) October 2017 epilepsy cohort study: Logo HZ (Draju HA) [55]Slightly invasive and acceptance bias; limited infection detection after CDTI delivery and in low-transmission areas [58]2 versus 4 snips impacts sensitivity [61]Selection criteria in trials (preference for higher microfilarial loads) and in epilepsy studies (onchocerciasis exposure associated with epilepsy) limit population representativeness [22,39,55] Blackfly breeding site surveys Vector breeding/presence prospection and pre-imaginal (larval and pupal) habitatsPrimarily river sites resembling S. damnosum s.l. habitatsFreshwater crab habitats for S. neaveiHand collection of Simulium spp. larvae and pupae from rocks/vegetationFreshwater crabs captured by hand or baited basket traps; blackfly preservation in 70% ethanolPresence/absence of simuliid immature stages; Simulium species identification, including non-anthropophagic speciesPresence/absence of crabs infested with S. neavei immature stages.Simulium breeding sites: 1) August-October 2015, August 2016, April and August 2017: Awo River, Kakoi River basin (Logo HZ: Thedeja HA; Nyarambe HZ: Nyalebbe HA), downstream Kakoi River basin (Nyarambe HZ: Afoyo HA), Kuda River basin (Angumu HZ: Kudieweka HA; Logo HZ: Draju HA; Nyarambe HZ: Kpanyi HA) and Koda River basin (Rethy HZ: Lokpa, Rassia HAs) [18]Crab prospections (for S. neavei): 2) October 2009: Awo River, Kakoi River basin (Logo HZ: Alla Wi Mo HA; Nyarambe HZ: Nyalebbe HA) [56]; 3) September 2015, June and August 2016: Awo River, Kakoi River basin (Nyarambe HZ: Lelo, Nyalebbe HAs), Kakoi River basin (Logo HZ: Draju HA) and Koda River basin (Rethy HZ: Lokpa, Rassia HAs) [18]Targeted prospection (no prior breeding-site mapping); incomplete spatial and seasonal coverage [18] Adult blackfly collections Identify anthropophilic (human-biting) Simulium species present in the area; when tested, detect ongoing transmission via O. volvulus-positive fliesInformal human landing catches (HLC) for adult (imaginal) blackfly collection at riverbank prospection sitesHLC “spot checks” (for 30–60 minutes) per site; captured flies preserved in 70% ethanol; blackfly morphological identification to species; heads and bodies separated; qualitative real-time triplex PCR (16S, ND5) for O. volvulus positivity per fly.Presence and species identification of anthropophagic blackfliesO. volvulus infection rate (bodies) and infective rate (heads)Informal HLCs Prospections: August, October and November 2017, February–April 2018: Kuda River basin (Logo HZ: Draju HA; Nyarambe HZ: Afoyo, Kpanyi HAs; Rethy HZ: Rassia HA) [18]No parity dissections; no formal collector rotation or fixed timetable to allow estimation of biting rates; seasonal and diurnal gaps; ethical concerns inherent to HLCs; incomplete spatial coverage of the focus [18]Abbreviations: CDTI = community-directed treatment with ivermectin; ESPEN = Expanded Special Project for Elimination of Neglected Tropical Diseases; HA = health area; HZ = health zone; REMO/REA = Rapid epidemiological mapping of onchocerciasis/Rapid Epidemiological Assessment.aCommunity survey data generated within the NSETHIO project [30] (see Methods [31]). Individual-level records are provided in S1 Data and summarised in Table C in S1 Appendix.
Epidemiological and entomological data sources and methods in the Kakoi–Koda onchocerciasis focus, Ituri Province, DRC.
Abbreviations: CDTI = community-directed treatment with ivermectin; ESPEN = Expanded Special Project for Elimination of Neglected Tropical Diseases; HA = health area; HZ = health zone; REMO/REA = Rapid epidemiological mapping of onchocerciasis/Rapid Epidemiological Assessment.
aCommunity survey data generated within the NSETHIO project [30] (see Methods [31]). Individual-level records are provided in S1 Data and summarised in Table C in S1 Appendix.
3.1.1 CDTI delivery.
Ivermectin delivery in the Kakoi-Koda focus differed between HZs and by target disease. For onchocerciasis control, CDTI began in Angumu HZ in 2009 (ESPEN repository-derived therapeutic coverages of 80–82% of the total population) and in Rethy HZ in 2012 (68–81% coverage). In contrast, in Nyarambe HZ, mass drug administration of ivermectin and albendazole for lymphatic filariasis commenced in 2016 (80–84% coverage) [21]. Logo and Mahagi HZs had not implemented CDTI as of 2025 [21]. Ivermectin delivery was temporarily interrupted in Ituri in 2020 due to the COVID-19 pandemic [21].
Beyond routine CDTI, the trials described in subsection 2.4 treated only their recruited participants. The 2010–2011 moxidectin trial administered single doses to 315 (8 milligrams of moxidectin) and 157 (150 micrograms of ivermectin/kilogram of body weight) participants in Draju and Kanga HAs (Logo HZ) [33,34]. Secondly, the 2017–2018 ivermectin proof-of-concept study gave one to three ivermectin doses to 197 persons living with epilepsy in Draju, Kanga, Walla, Ulyeko, Thedeja HAs (Logo HZ) [35,36]. Only 1.5% (3/197) of these participants self-reported prior ivermectin use [35]. Thirdly, the 2021–2023 moxidectin trial enrolled additional participants on moxidectin or ivermectin (trial results pending) [22,37], and fourthly, the ongoing 2021–2026 trial delivers one to three annual or five biannual doses (results are pending for both trials) [22,38]. At the 2021–2023 screening, self-reported ivermectin use in the preceding five years was 0.4% (29/7,547) in Draju, Kanga and Thedeja HAs (Logo HZ) and 0.9% (9/1,047) in Kpanyi HA (Nyarambe HZ) [40].
In addition to the clinical trials, two epilepsy case-control surveys provided local verification of ivermectin intake. The first survey was conducted in August 2015, with a population sampled aged 3–75 years (median: 22 years, IQR: 14–30 years) and 52.4% females. The second survey was conducted in October 2015, with a population sampled aged 4–35 years (median: 17 years, IQR: 12–24 years) and 53.6% females. The former survey (August) found a self-reported ivermectin intake in 2014 of 1.5% (1/69) in Logo HZ (Draju HA) and of 75.4% (43/58) in Rethy HZ (Kpandroma, Lokpa HAs) [52,53]. The latter survey (October) found a self-reported ivermectin intake in 2014 of 9.1% (4/45) in Logo HZ (Draju HA) and of 73.3% (11/15) in Rethy HZ (Lokpa HA) [52,53]. Among respondents who reported taking ivermectin in the latter survey, the median cumulative number of ivermectin rounds taken was 3 (IQR: 3–3; range: 0–3 rounds).
A self-reported community survey conducted in 2021 in Nyarambe HZ (Kpanyi HA) among ivermectin-eligible children aged 5–9 years, reported here for the first time, recorded 2020 ivermectin coverage of 91.6% (87/95) (S1 Data). Among treated children, the median cumulative number of ivermectin rounds received by 2020 was 2 (IQR: 2–2; range: 1–3 rounds). Participants had a median age of 7 years (IQR: 7–9 years), and 56.4% were female.
3.1.2 Longitudinal trends in O. volvulus infection indicators.
Across data sources, indicators of O. volvulus infection declined between early observations (REMO 2003; skin‐snip screening data in 2010–2011) and more recent surveys (in 2015–2023). To document this pattern, we first summarise baseline endemicity from nodule palpation surveys, then present serological evidence (all-age exposure and child anti-Ov16 as an indicator of recent transmission), and finally describe skin-snip prevalence and intensity between the 2010–2011 and 2021–2023 moxidectin trial and OAE studies (2015–2017).
Nodule palpation prevalence to establish baseline endemicity
A proportion of adult O. volvulus worms reside in subcutaneous nodules or onchocercomata [62], making nodule palpation a useful REA method for the evaluation of prevalence in areas of moderate to high endemicity. In 2003, REMO/REA nodule palpation identified several areas as meso- or hyperendemic (≥20% nodule prevalence) for onchocerciasis, permitting an initial delineation of the Kakoi-Koda focus (Fig 2) [23]. A median of 30 individuals (IQR: 30–40) aged ≥20 years per HA (one village) were examined, of which 82.7% (617/746) were male.
Hyperendemicity (nodule prevalence ≥40%) was concentrated between the Awo River (northeast Kuda branch) and the Kakoi, Kuda and Lebu River basins, in Bessi, Dabu and Langa HAs (Angumu HZ; 70–90%), Draju and Kanga HAs (Logo HZ; 98% and 70%) and Afoyo HA (Nyarambe HZ; 52%). Mesoendemicity (nodule prevalence ≥20% but <40%) extended upstream in the Kakoi and the Koda and Loda River basins, in Aree and Musongwa HAs (Angumu HZ; 36% and 35%), Pundiga HA (Nyarambe HZ; 30%) and Rassia HA (Rethy HZ; 37%). Hypoendemic areas (nodule prevalence ≥5% but <20%) were recorded around the Awo River in Thedeja HA (Logo HZ; 7%) and Nyalebbe HA (Nyarambe HZ; 16%). An additional survey in 2009 in Otha HA classified it as non-endemic (Logo HZ; 4%) [56]. (Areas with <10% microfilarial prevalence are considered non-endemic/sporadic endemicity, corresponding to a nodule prevalence <5% [16,63,64].)
Using similar methods, a 2015 REA study was conducted in several villages within three HAs that reported high OAE prevalence [52]. Nodule prevalence was 34.6% in Draju (Logo HZ), and 29.6% in Rassia and 17.2% in Lokpa (Rethy HZ). Among those with nodules, the median number was one (IQR: 1–1; range: 1–6). In November 2017, a further REA conducted alongside a study of urinary N-acetyltyramine-O,β-glucuronide [57], and whose nodule findings are reported here for the first time, palpated 94 men aged ≥20 years in villages of Logo HZ reporting a high OAE prevalence. Nodule prevalence was 44.4% in Draju, 56.8% in Kanga and 20.0% in Walla. Among those with nodules, the median number was one (IQR: 1–1; range: 1–4).
A last nodule palpation survey in October 2017 examined 38 adults aged ≥20 years living with epilepsy in Draju HA (Logo HZ), including the same villages as in the 2003 and 2015 surveys, and recorded a nodule prevalence of 21.1% (95% CI: 10.1–37.8) [55]. Denominators, villages sampled, endemicity classifications and 95% confidence intervals for all nodule surveys are given in Table A in S1 Appendix.
Anti-Ov16 serological surveys to assess O. volvulus cumulative exposure
Anti-Ov16 serology was measured (with whole blood) using the SD Bioline anti-Ov16 RDT (Onchocerciasis IgG4 rapid test, Abbott Standard Diagnostics, Inc., Yongin, Korea; method detailed in Table 1). Anti-Ov16 serosurveys conducted during 2015–2017, among residents aged ≥3 years and, in one survey, among men aged ≥20 years, indicate high cumulative exposure in both Logo and Rethy HZs (Table B in S1 Appendix), in agreement with 2003 REMO meso- to hyperendemic classifications in Fig 2. Seropositivity was generally higher in Draju HA (Logo HZ).
Community sampling (among 921 residents aged ≥3 years) in Logo in 2016 found that Draju seroprevalence was elevated at 36.1% (95% CI: 31.6–40.8) compared with 25.8% (95% CI: 22.0–30.1) in Kanga HA (Table B in S1 Appendix) [54]. The estimate for Ulyeko HA is based on a very small sample (2/7 seropositive), providing limited information beyond indicating some O. volvulus exposure in that HA. In 2017, the same 94 men aged ≥20 years palpated for nodules in Draju, Kanga and Walla HAs were also tested by anti-Ov16 RDT, and cumulative lifetime exposure was likewise high, at 40.7% (95% CI: 23.0–61.0), 64.9% (95% CI: 47.4–79.3) and 26.7% (95% CI: 13.0–46.2) respectively [57].
Epilepsy case-control and cohort samples from 2015–2017 showed substantial cumulative exposure in parts of Logo and Rethy but were not population-representative (Table B in S1 Appendix). In the 2015 epilepsy case-control, seroprevalence in Draju was 41.2% (95% CI: 32.2–50.8), closely followed by Rassia HA (Rethy HZ) at 37.8% (95% CI: 22.9–55.2), and lower in Lokpa HA (Rethy HZ) at 29.4% (95% CI: 17.9–44.0) [52,53]. These patterns are consistent with the 2015 REA described above, with moderate nodule prevalence in Draju and Rassia (30–35%) and lower prevalence in Lokpa (17%). In the 2017 epilepsy cohort, a seroprevalence of 64.4% (95% CI: 52.2–75.0) was documented in Draju, statistically significantly higher than the 28.0% (95% CI: 22.9–33.6) seroprevalence from the pooled Kanga/Ulyeko/Thedeja/Walla HAs (Logo HZ) cohort [55].
Age- and sex-specific anti-Ov16 seroprevalence from the 2016 community survey in Logo HZ (Table B in S1 Appendix) is shown in Fig 3. Seroprevalence rose steeply from childhood to early adulthood and then plateaued around 60–70% in older adults, consistent with the hyperendemic status indicated by the 2003 REMO survey. Seroprevalence tended to be higher in males in the younger age groups, but higher in females in the older age groups. In a logistic regression including a sex-by-age-group interaction and adjusting for HA, there was no strong evidence of sex differences up to 40 years of age (odds ratio female versus male (ORf/m): 0.77, p = 0.19 for ages 3–30 years; ORf/m: 0.92, p = 0.85 for 31–40 years), although point estimates suggested slightly higher exposure in men. In contrast, among adults aged >40 years, women had markedly higher seroprevalence than men (ORf/m: 2.46, p = 0.004).
Age-specific anti-Ov16 seroprevalence by sex in the 2016 community survey in Logo Health Zone (Draju, Kanga and Ulyeko Health Areas) [54].
Red circles (joined by red solid line) show seroprevalence estimates with 95% Wilson confidence intervals (error bars) by age group overall, with green squares indicating males and blue triangles indicating females (male and female estimates are slightly offset horizontally for better visualisation).
An ESPEN repository-derived anti-Ov16 ELISA dataset from 2015 targeted non-endemic villages surrounding the Kakoi-Koda focus, and therefore is presented Text B in S1 Appendix [22].
Child anti-Ov16 RDT serological surveys to indicate O. volvulus ongoing transmission
In Logo HZ (Draju HA), the 2015 epilepsy case-control survey identified anti-Ov16 RDT seropositivity in children aged 3–6 (1/7) and 7–10 (2/19) years (Table C in S1 Appendix) [52,53]. In the subsequent 2016 community survey conducted in the same locality, no child aged 3–6-years was seropositive (0/70), whereas 10.3% of 7–10-year-olds were (7/68) [54]. A similar pattern was observed in Kanga HA (Logo HZ) in 2016, with seroprevalence of 2.2% among 3–6-year-olds (2/90) and 9.6% among 7–10-year-olds (7/73). No seropositive children were identified in the 2017 epilepsy cohort across Draju, Kanga, Ulyeko, Thedeja, and Walla HAs (Logo HZ; 0/56) [55]. In 2018, a smaller community survey in Kanga and Walla, reported here for the first time, detected no seropositive 3–6-year-olds (0/4 in Kanga, 0/14 in Walla) and one seropositive 7–10-year-old (1/21 in Kanga, 0/21 in Walla; Table C in S1 Appendix).
In Rethy HZ, one of 17 children tested in Lokpa and Rassia HAs was seropositive in the 2015 case-control (Table C in S1 Appendix) [52,53]. In Nyarambe HZ (Kpanyi HA), none of the 95 children aged 7–9 years tested in 2021 was seropositive in a community survey reported here for the first time (Table C in S1 Appendix).
Skin-snip microscopy surveys for moxidectin trials
Skin-snip microscopy data were assembled from sources using two different protocols: 1) moxidectin trial screenings (2010–2011 and 2021–2023), which obtained four snips per participant from community-recruited residents aged ≥12 years; and 2) other surveys (2015–2017), which obtained two snips per participant in OAE case-control and cohort designs (methods detailed in Table 1). Because snip number and study design differ, prevalence and intensity are only compared within (but not between) these two groups.
In the 2010–2011 moxidectin trial screening, large numbers of residents were screened in Logo HZ, mostly in Draju (number = 1,149) and Kanga (n = 161) HAs (Table 2) [22]. Additionally, a smaller number of residents were screened in Nyarambe HZ (Kpanyi HA; n = 36). Village-level sample sizes were small and heterogeneous (median: 7, IQR: 3–25, range: 1–324 residents per village). O. volvulus microfilarial prevalence reached 79% in Draju (908/1,149) and 72% in Nyarambe, consistent with the abovementioned REMO (2003) hyperendemic classifications and all-age anti-Ov16 findings (2015–2017; Table B in S1 Appendix).
10.1371/journal.pntd.0014164.t002Table 2Skin‐snip results from cross-sectional moxidectin trial screenings in 2010–2011 and 2021–2023, by age group, health zone and health area [22]. Community-recruited participants aged ≥12 years provided four skin snips each. Onchocerca volvulus infection prevalence is shown with Wilson score 95% confidence intervals, and infection intensity (microfilariae per milligram of skin). The proportion of females and males surveyed is not available.Health AreaStudy numbercYearsNumber examined aged ≥18; 12–17 yearsSkin snip microfilaria-positive/Total examined(prevalence %, 95% CI)Mean infection intensity overall (mean mf+ intensity; range)mf/mg skinAll ages, aged 12–93 years Aged 12–17 years Logo Health Zone Draju12010-111,057; 92908/1,149 (79.0, 76.5–81.3)70/92 (76.1, 65.9–84.1)26.2 (33.1; 0.1–299.4)22021-232,803; 1,212363/4,015 (9.0, 8.2–10.0)38/1,212 (3.1, 2.3–4.3)1.2 (13.0; 0.1–177.8)Kanga12010-11151; 10111/161 (68.9, 61.1–75.9)4/10 (40.0, 13.7–72.6)d17.1; (24.8; 0.1–200.8)22021-231,967; 706231/2,673 (8.6, 7.6–9.8)26/706 (3.7, 2.5–5.4)1.1; (13.2; 0.1–99.2)Thedeja22021-23747; 11232/859 (3.7, 2.6–5.3)0/112 (0.0, 0.0–4.1)NA; (NA; 0.3–154.8)Ambere/Buu/Jupahoy/Ndrele/Ulyeko/Wallaa12010-1157; 630/63 (47.6, 35.1–60.5)5/6 (–e)NA; (NA; 0.2–91.1) Nyarambe Health Zone Kpanyi1b2010-1136; 026/36 (72.2, 54.6–85.2)010.6; (14.6; 0.1–135.6)22021-23690; 35730/1,047 (2.9, 2.0–4.1)0/357 (0.0, 0.0–1.3)0.4; (13.2; 0.2–53.8)Abbreviations: CI = confidence interval; IQR = interquartile range (1st quartile to 3rd quartile); mf = microfilariae; mf + intensity = microfilarial load among those with microfilaria-positive skin snips; mg = milligram; NA = not available, as the data were only available aggregated.a Contiguous health areas in Logo Health Zone: Ambere (12/14 positive), Buu (3/4), Jupahoy (4/8), Ndrele (0/10), Ulyeko (4/17), Walla (7/10).b Includes five adults who were microfilaria-positive by skin-snip microscopy from the Lelo Health Area in Nyarambe Health Zone, bordering Kpanyi.cStudy number is the numerical label (1–2) grouping rows belonging to the same data collection round; identical study numbers indicate the same study conducted in multiple health areas.dSmall sample size (number = 10–30).ePrevalence and 95% confidence interval are not reported for very small samples (number < 10).
Skin‐snip results from cross-sectional moxidectin trial screenings in 2010–2011 and 2021–2023, by age group, health zone and health area [22]. Community-recruited participants aged ≥12 years provided four skin snips each. Onchocerca volvulus infection prevalence is shown with Wilson score 95% confidence intervals, and infection intensity (microfilariae per milligram of skin). The proportion of females and males surveyed is not available.
Abbreviations: CI = confidence interval; IQR = interquartile range (1st quartile to 3rd quartile); mf = microfilariae; mf + intensity = microfilarial load among those with microfilaria-positive skin snips; mg = milligram; NA = not available, as the data were only available aggregated.
a Contiguous health areas in Logo Health Zone: Ambere (12/14 positive), Buu (3/4), Jupahoy (4/8), Ndrele (0/10), Ulyeko (4/17), Walla (7/10).
b Includes five adults who were microfilaria-positive by skin-snip microscopy from the Lelo Health Area in Nyarambe Health Zone, bordering Kpanyi.
cStudy number is the numerical label (1–2) grouping rows belonging to the same data collection round; identical study numbers indicate the same study conducted in multiple health areas.
dSmall sample size (number = 10–30).
ePrevalence and 95% confidence interval are not reported for very small samples (number < 10).
Age-stratified skin snip results in Logo in 2010–2011 showed no clear signs of reduced infection in adolescents (Table 2). In particular, in Draju, overall prevalence was 79.0% (95% CI: 76.5–81.3), similar to the prevalence in 12–17-year-olds of 76.1% (95% CI: 65.9–84.1); in Kanga, overall prevalence was 68.9% (95% CI: 61.1–75.9) and prevalence among 12–17-year-olds was 40.0% (95% CI: 13.7–72.6), with the wide adolescent CI overlapping the adult estimate.
In the 2021–2023 moxidectin trial screening, sampling effort increased across the same HAs of Draju (n = 4,015), Kanga (n = 2,673) and Kpanyi (n = 1,047; Table 2), with larger village-level samples (median: 50, IQR: 21–218, range: 3–950 residents per village). Prevalence was markedly reduced in all three HAs (approximately 3–9% overall prevalence). Declines were most pronounced in younger age groups. For example, in Draju, the prevalence among 12–17-year-olds fell from 76.1% (95% CI: 65.9–84.1) in 2010–2011 to 3.1% (95% CI: 2.3–4.3) in 2021–2023. In Kpanyi, although the 2010–2011 sample was limited, repeat adult sampling across the same villages showed a reduction from 72.7% (16/22) to 2.0% (1/49) (Fisher’s exact p < 0.001). Thedeja HA (in Logo HZ) was also screened in 2021–2023 (but not in 2010–2011) as the trial expanded sampling to identify additional O. volvulus-infected residents for enrolment, and it showed the lowest microfilarial prevalence among the four HAs (3.7%, 95% CI: 2.6–5.3), consistent with its hypoendemic status according to the 2003 REMO surveys.
Infection intensity mirrored these prevalence declines (Table 2). Community infection intensity (i.e., microfilariae per milligram of skin) was substantially lower in 2021–2023 than in 2010–2011. Illustratively, Draju decreased from 26.2 (range: 0.1–299.4) to 1.2 (range: 0.1–177.8), Kanga from 17.1 (range: 0.1–200.8) to 1.1 (range: 0.1–99.2) and Kpanyi from 10.6 (range: 0.1–135.6) to 0.4 (range: 0.2–53.8). This decrease in microfilarial load was also observed when only considering those with microfilaria-positive skin snips (i.e., mf+ intensity in Table 2).
In the smaller 2010–2011 screening sites, microfilaria-positive skin snips were frequent in Ambere (12/14) and Walla (7/10) HAs, which border the Draju and Kanga HAs classified as hyperendemic by REMO in 2003, but absent in the northernmost HA tested (Ndrele, 0/10), which borders the non-endemic Ukebu Ngali HA (Table 2).
Skin-snip microscopy surveys from other studies
Across the 2015–2017 epilepsy case-control and cohort surveys in Logo (e.g., Draju HA) and Rethy (e.g., Lokpa and Rassia HA) HZ, the highest all-age skin-snip prevalence values were consistently observed in Draju (range: 46–63%) compared to more moderate microfilaria-positive skin-snip prevalence values in other HAs (range: 20–47%; Table D in S1 Appendix), concordant with the all-age anti-Ov16 seroprevalence for these areas (Table B in S1 Appendix) [52–55]. Infection intensity was relatively high in most surveyed HAs (range: 13–93 microfilariae per skin snip), excluding Lokpa (range: 2–8 microfilariae per skin snip; Table D in S1 Appendix), consistent with Lokpa’s hypo- to mesoendemicity status by nodule prevalence (2003–2015) compared to meso- to hyperendemicity in Rassia and Draju.
Lower proportions of microfilaria-positive skin snips were detected among children aged 3–11 years in Logo HZ (14–33% in Draju HA; Table D in S1 Appendix) compared with adolescents (48–60% in Draju HA among 12–17-year-olds), in agreement with the low anti-Ov16 seroprevalence (by RDT) in Logo among 3–10-year-olds (0–19% in 2015–2018; Table C in S1 Appendix). In contrast, child infection patterns in Rethy HZ did not show a similarly marked decline (33% in Rassia HA; Table D in S1 Appendix) relative to adolescents (30% in Rassia among 12–17-year-olds).
An ESPEN repository-derived skin-snip dataset from 2015 sampled non-endemic villages surrounding the Kakoi-Koda focus, and therefore is presented Text B in S1 Appendix [22].
3.1.3 Vector species and transmission ecology.
To characterise potential vectors and where transmission may persist, we combined information from targeted larval/pupae breeding site prospections in both crab-associated and non-crab river habitats, together with informal “spot-check” HLCs to identify anthropophagic Simulium species and individual PCR testing of a subset for O. volvulus 16S and ND5 genes across the main basins of the focus (methods detailed in Table 1).
Breeding sites prospection
Crab-associated prospections for the S. neavei group conducted in October 2009 detected S. neavei larvae at one site within the focus, specifically at the Kakoi River basin (larvae in 11/12 crabs in Lelo HA, Nyarambe HZ) [56]. Two crabs from the south-eastern Awo River (Nyalebbe HA of Nyarambe HZ) were not infested with larvae, and no crabs were found further north-west at the limit of the focus (Alla Wi Mo HA, Logo HZ). In 2015–2016, no infested crabs were detected despite targeted sampling along the Kuda River basin (Logo HZ, Draju HA: 0/35 crabs from nine sites), the Koda River basin (Rethy HZ, Lokpa HA: 0/2 crabs from three sites; Rassia HA: 0/4 crabs from one site), and the Loda River basin (Lokpa HA: 0/30 crabs from three sites) [18]. No crabs were found in 2015–2016 along the south-eastern Awo River near one of the 2009 capture points (Nyalebbe HA). Overall, no active crab-associated S. neavei breeding was detected in 2015–2016 at the prospected locations.
Regarding non-crab Simulium larval breeding habitats, between 2015 and 2017, larval and pupal prospections documented breeding of S. dentulosum and S. vorax at several basins: 1) Awo (Kakoi River basin) in Logo HZ, Thedeja HA: S. dentulosum, S. vorax; and Nyarambe HZ, Nyalebbe HA: S. vorax; 2) downstream Kakoi River basin in Nyarambe HZ, Afoyo HA: S. vorax; 3) Kuda River basin in Angumu HZ, Kudieweka HA: S. vorax; Logo HZ, Draju HA: S. dentulosum, S. vorax; and Nyarambe HZ, Kpanyi HA: S. vorax; and 4) Koda River basin in Rethy HZ, Lokpa HA: S. dentulosum; and Rassia HA: S. dentulosum [18]. Breeding of several non-anthropophagic Simulium species was also recorded [18].
Adult female blackfly collections by informal “spot-check” HLCs
Informal HLCs spot checks undertaken in August–November 2017 and February–April 2018 detected Simulium (Anasolen) dentulosum [65] and S. vorax Pomeroy [18,56,66] biting humans along the Kuda River basin across multiple HZs (HA): Angumu (S. dentulosum and S. vorax in Dabu), Logo (S. vorax in Draju), Nyarambe (S. dentulosum and S. vorax in Afoyo; and S. dentulosum in Kpanyi) and Rethy (S. dentulosum in Rassia).
A subset of the collected blackflies (155/161 S. dentulosum and 4/23 S. vorax) was processed individually for triplex real-time PCR (heads/bodies separated) to detect O. volvulus DNA. Among S. dentulosum, 30.3% were body-positive for O. volvulus (47/155; 95% CI: 23.3–38.3) and 11.0% were head-positive (infective; 17/155; 95% CI: 6.7–17.2). Four S. dentulosum flies were positive in both compartments. For S. vorax, 1/4 (25%) bodies and 0/4 (0%) heads were positive.
3.2 Geospatial analysis
An interactive ArcGIS web map aggregating epidemiological, entomological and land-cover layers (REMO/REA 2003–2015; skin-snip screening 2010–2011, 2015–2017, 2021–2023; anti-Ov16 surveys 2015–2021; informal HLC and breeding site prospections; forest loss 2001–2024; administrative boundaries; rivers/streams) is publicly available at https://arcg.is/1PDyO0. A README file is available in S1 Appendix Text A.
3.2.1 Individual and spatial concordance of recent transmission indicators.
Paired anti-Ov16 RDT and skin-snip microscopy results were available for children aged 3–10 years from the 2015 epilepsy case-control [53] and 2017 epilepsy cohort [55] studies (n = 83). Agreement between tests was high by simple proportion (92.8%), while chance-corrected agreement was moderate (κ = 0.47, 95% CI: 0.11–0.82; −1 to 1 scale), consistent with low prevalence. There was no evidence that the tests differed in overall positivity rates (mid-p McNemar p = 0.125). Using skin-snip microscopy as reference, anti-Ov16 RDT in the field had 37.5% sensitivity (95% CI: 8.5–75.5) and 98.7% specificity (95% CI: 92.8–100.0).
Anti-Ov16 seroprevalence in children aged 3–10 years sampled from the community (2016–2021; including previously unreported data from the NSETHIO programme [30,31] provided in Table C in S1 Appendix and S1 Data) and adolescent (12–17 years) microfilaria-positive skin-snip prevalence in 2021–2023 (second moxidectin trial screening) showed a coherent, geographically structured pattern (see interactive map https://arcg.is/nb45e1). Positive surveys were clustered along north-eastern Muda River tributaries of the Kuda River basin, and north-western tributaries of the Lebu River basin in Draju and Kanga HAs (Logo HZ), with 6/110 children seropositive for anti-Ov16 IgG4 and 40/1,010 adolescents testing as microfilaria-positive by skin-snip microscopy. Adjacent Kuda River tributaries upstream of the Muda River showed additional low-positive signals, with children's serology yielding mixed results across nearby villages (4/127 seropositive), and adolescent microfilarial prevalence mirroring this pattern (27/908), producing a mosaic of zero to very low positivity in surveys conducted in Draju and along the borders with Ulyeko and Buu HA (Logo HZ).
In contrast, the north-eastern Kuda River branch (Kpanyi HA, Nyarambe HZ) showed no evidence of recent transmission, with 0/82 children seropositive and 0/357 adolescents skin-snip microfilaria-positive. Similarly, no evidence of recent transmission was detected in the surveyed locations in the Awo River basin or in the Kakoi River tributaries (including the sections of Suu and Ryeda rivers north of the Muda/Kuda), where only skin snips were undertaken (0/112; in Thedeja HA, Logo HZ).
Findings from the epilepsy case-control (2015) and the epilepsy cohort (2017) studies were consistent with this spatial pattern. Among 3–10-year-olds in the Kuda River basin (Draju), 6/35 skin snips and 3/30 anti-Ov16 tests were positive. Also, between the Koda and Loda River basins (Lokpa and Rassia HAs, Rethy HZ), 6/29 skin snips and 1/17 anti-Ov16 tests were positive. Together, these data indicate that field anti-Ov16 RDT results in children were broadly concordant with the spatial gradient observed for adolescent skin-snips.
3.2.2 Landscape change and tree canopy loss.
Remote-sensing and field observations indicate substantial but heterogeneous tree-cover change across the Kakoi–Koda focus [67]. Agriculture (e.g., coffee, rice, tobacco and cotton), logging and conflict-related population movements have contributed to progressive deforestation, already documented in western South Ituri by the late 2000s [67]. Across the five HZs, 14,480 hectares met the dense forest definition (≥70% tree cover) in 2000, of which 95.7% lay in Rethy HZ (Table E in S1 Appendix). From 2001 to 2024, cumulative loss of all forest (≥30% tree cover) at the HZ level ranged from 3.4% to 7.1%, whereas loss of dense forest was 39.3% in Angumu, 62.6% in Logo, 72.5% in Mahagi, 84.9% in Nyarambe and 12.8% in Rethy. Dense forest loss was concentrated in 2001–2012 across Angumu, Logo, Mahagi and Nyarambe, with additional loss in 2017–2019 in Logo and in 2019 in Mahagi (Fig A in S1 Appendix). Rethy, which holds almost all the remaining dense forest of the focus, shows instead a progressive pattern of dense forest clearance that has accelerated since 2017.
At the HA level, dense forest loss was greatest in the HAs classified as hyperendemic by REMO (2003) or the 2010–2011 trial skin-snip population screening. Particularly, in Logo HZ, Draju and Kanga lost 89.6% and 74.8% of their 2000 dense forest by 2024, respectively. In Nyarambe HZ, Kpanyi lost 83.8%. The much smaller dense-forest remnants of Dabu (Angumu HZ), Afoyo (Nyarambe HZ) and the mesoendemic Pundiga HA (Nyarambe HZ) were cleared entirely. Losses were more modest in the other meso- and hyperendemic HAs, ranging from 1.9% in Aree to 39.4% in Langa (Angumu HZ) and 34.4% in Rassia (Rethy HZ). Health-area estimates for dense forest loss, with the 2000 baseline areas on which they are calculated, are given in Table E in S1 Appendix.
At the river basin level, canopy loss was spatially heterogeneous across the focus (Table 3, Fig 4 and Fig B in S1 Appendix). The highest proportional losses were concentrated in the hyperendemic belt between Angumu, Logo and Nyarambe HZs (Fig 4), where dense forest has been extensively cleared (Fig B–F in S1 Appendix). This includes the Awo River basin (74% deforested; Table 3), the Muda River tributaries in the Kuda River basin (78% deforested), the northern Lebu River basin (92% deforested), and the northern Koda and Loda River basins (81% deforested). Small remnants of dense forest are located along the north-western Kakoi River tributaries (55% deforested; Fig G in S1 Appendix). Larger mosaics of dense forest persist in the mid- and downstream Koda and Loda River basins and around Mount Aboro (Rethy HZ), but together these have also lost about a third of their 2000 dense forest cover, particularly in riparian (river-bank) zones (Fig H in S1 Appendix).
10.1371/journal.pntd.0014164.t003Table 3Dense forest (≥70% tree cover in 2000) and its cumulative loss by 2024, by river basin, in the Kakoi–Koda onchocerciasis focus. Figure references are to the corresponding maps in S1 Appendix.River basinMain health areasDense forestIn 2000 (hectares)Lost 2001–2024 (hectares)Lost (%)Awo (Fig C)Buu, Leo, Thedeja352674Muda tributaries, Kuda basin (Fig D)Draju, and borders with Ambere, Kanga, Kpanyi695478Northern Lebu (Fig E)Kudieweka, adjacent to Kanga393692Northern Koda and Loda (Fig F)Kpandroma–Walla–Lokpa boundaries322681North-western Kakoi tributaries (Fig G)Langa11655Mid- and downstream Koda (Fig H)Rassia49516233Southern Loda (Fig H)Lokpa191053Mount Aboro reserve (Fig H)Uketha21314Note: Hectare = 10,000 square meters.
Dense forest (≥70% tree cover in 2000) and its cumulative loss by 2024, by river basin, in the Kakoi–Koda onchocerciasis focus. Figure references are to the corresponding maps in S1 Appendix.
Note: Hectare = 10,000 square meters.
Percentage of dense forest cover lost between 2001 and 2024 in the Kakoi-Koda onchocerciasis focus.
Health areas (black thin boundaries) are shaded by the percentage of dense forest (≥70% tree cover in 2000) that was lost by 2024, grouped into 10 quantile classes (from 0 to 100% loss). Health zone boundaries for Angumu, Logo, Mahagi, Nyarambe and Rethy are shown as bold grey lines. The map was produced in ArcGIS Pro (Esri, Redlands, CA, USA) using publicly available GRID3 COD – Health Areas v5.0 https://doi.org/10.7916/nnew-da26 [25] and GRID3 COD – Health Zones v5.0 https://doi.org/10.7916/d8rn-6e24 [26] boundaries and the Hansen Global Forest Change dataset (30-metre resolution; per cent tree cover in 2000 and annual tree loss, 2001–2024) [41,42].
4. Discussion
The Kakoi–Koda onchocerciasis focus in the DRC spans five HZs. Baseline nodule prevalence mapping (REMO, 2003) indicated hyperendemicity in parts of Logo, Nyarambe and Angumu HZs, with mesoendemicity in Rethy and possibly Mahagi HZs. Across independent data streams spanning two decades, onchocerciasis infection indicators in the focus have fallen sharply since the 2010–2011 (skin-snip) community screening for the Phase III moxidectin clinical trial [33,39], which at the time confirmed hyperendemicity in Logo and Nyarambe. Age (and sex) profiles of all-age anti-Ov16 surveys in 2015–2017 confirmed substantial cumulative exposure in parts of Logo and Rethy HZs, consistent with the baseline mapping.
By contrast, children-only (aged 3–10 years) anti-Ov16 seroprevalence from 2016 onward was uniformly low or zero in most surveyed HAs of Logo, Nyarambe and Rethy HZs that had been hyperendemic at baseline, with some positives mostly in older children (7–10 years), consistent with a reduction in the force of infection. Skin-snip screening corroborated this trajectory, with hyperendemic infection prevalence and intensity in 2010–2011 declining to hypoendemic levels by 2021–2023 in Draju and Kanga (Logo HZ), with the steepest relative declines in adolescents (the youngest group sampled using skin-snip microscopy). In Nyarambe (Kpanyi HA), where early sample sizes were small, prevalence in adults significantly fell from 72% to 3% in villages surveyed at both time points. In Rethy HZ, REMO categories changed from borderline hyperendemic (2003) to what would have been considered mesoendemic (2015), the latter result mirrored by microfilarial prevalence and intensity in studies among persons with epilepsy (2015). Spatially, residual transmission signals clustered along limited stretches of the Muda/Kuda and Lebu River basins (and possibly between Koda and Loda River basins). Other river basins, such as sections of Awo and Kakoi, showed no evidence of recent transmission.
The exact onset of the endemicity decline cannot be empirically dated due to the absence of earlier microfilarial data. However, none of the children aged 3–6 years tested in Draju (Logo HZ) in 2016 were anti-Ov16 seropositive (0/70). As these children were born approximately between 2010 and 2013, this finding is consistent with very limited transmission from around 2010 onwards. By 2021–2023, infection prevalence and intensity had dropped to low levels in previously hyperendemic HAs in Logo and Nyarambe HZs. In Logo, the evidence is consistent with sustained reductions in the force of infection for more than a decade.
The age-specific community anti-Ov16 seroprevalence profile observed in Logo HZ in 2016, with very low seroprevalence in young children, followed by a steep rise between 7 and 30 years of age and a plateau thereafter, is qualitatively similar to trajectories predicted for settings in which transmission has been substantially suppressed for one to two decades [68]. Although Logo HZ has not been under routine CDTI, analogous age patterns could result from a prolonged reduction in the force of infection driven by ecological change and vector species shifts and density declines. The marked decline in microfilarial prevalence and community infection intensity between the 2010–2011 and 2021–2023 moxidectin trial screenings are also broadly consistent with modelled trajectories for settings where transmission has declined over 15 years or more by 2021–2023 [68]. Transmission-modelling analyses using the microfilarial and anti-Ov16 seroprevalence data compiled here would be needed to test this quantitatively.
Vector ecology provides a plausible mechanism for changing transmission patterns [18]. Baseline meso- and hyperendemic onchocerciasis clusters at the Kakoi-Koda focus lay predominantly along escarpment slopes between higher and lower elevations, consistent with rapids suitable for Simulium breeding (see Fig 2 and relief model of the focus in [18]). The Simulium neavei group is phoretically associated with freshwater crabs and breeds in shaded streams, where its immature stages attach to crabs for transport and feeding [69]. While S. neavei is sensitive to canopy opening and habitat disturbance [46,70], S. dentulosum has been collected biting humans in the Ituri highlands and may act as a vector in more open habitats, with S. vorax possibly also contributing to transmission [18].
Historical information suggests that the S. neavei group occurred locally or in nearby Ituri rivers [71]. However, recent entomological work identified Simulium dentulosum and S. vorax as the anthropophagic species currently biting within the focus, with O. volvulus ND5-positive bodies (and for S. dentulosum, also heads), indicating parasite circulation along the Kuda River system in 2017–2018 [18]. In contrast, surveys since 2015 did not detect any active crab-associated S. neavei breeding in the prospected reaches (only one site with infested crabs was documented in Kakoi River in 2009) [18,56], consistent with its apparent disappearance from the focus. This pattern, together with progressive deforestation and canopy opening, is compatible with reduced shaded-stream habitat and disruption of crab-associated breeding, similar to the disappearance of S. neavei observed after bush-clearing in a hypoendemic focus in Nyanza Province, Kenya [72]. In several Ugandan onchocerciasis foci, the disappearance of S. neavei has likewise been attributed to deforestation [73]. These observations are consistent with the hypothesis proposed by Post et al. [18] of a shift in the local vector community from S. neavei to more open-habitat species (S. dentulosum and S. vorax), with lower overall vectorial density and/or capacity.
CDTI histories were heterogeneous across the focus. Angumu and Rethy HZs had long-running CDTI programmes for onchocerciasis since, respectively, 2009 and 2012, and Nyarambe HZ implemented mass drug administration of ivermectin and albendazole from 2016 for lymphatic filariasis, all programmes reporting high therapeutic coverage. In contrast, no CDTI was delivered in Logo or Mahagi HZs. Beyond routine delivery, microfilaricidal treatment had been provided to a small subset of residents recruited through moxidectin–ivermectin clinical trials (2010–2011; 2021–2026) [22,33] and an ivermectin trial among persons with epilepsy (2017–2018) [35,36]. Although the extent of these treatments was circumscribed rather than population-wide, enrolment often focused on individuals with higher microfilarial loads (to assess drug effects on infection intensity or seizure outcomes). Therefore, these targeted treatments may have contributed, to a limited extent, to the area-wide decline observed.
The marked onchocerciasis prevalence decline in Logo despite the absence of routine CDTI is compatible with a potential contribution from ecological drivers, particularly canopy loss along streams, which could have reduced suitable breeding habitat for S. neavei and constrained transmission to short river segments where anthropophagic Simulium species remain. Their vector competence and ability to maintain transmission are uncertain. The concordance between very low-to-absent anti-Ov16 seroprevalence in children, decreasing adolescent and adult infection prevalence and intensity, and the spatial contraction of transmission suggested by the evidence to the Muda/Kuda–Lebu rivers corridor (where CDTI has not been delivered) supports prioritising this corridor for further investigation. Future transmission modelling could account for both programmatic exposure (including the targeted trial doses) and ecological change when attributing the observed declines.
Two practical surveillance points emerge from our study. Firstly, anti-Ov16 RDT findings among children aged 3–10 years broadly reproduced the spatial gradient seen in skin snips, despite diagnostic limitations (limited sensitivity and RDT inability to distinguish ongoing from past infection) [58]. In our paired analysis of skin-snip microscopy and anti-Ov16 RDT in children, the field RDT showed low sensitivity (38%, 95% CI: 9–76) and high specificity (99%, 95% CI: 93–100) against skin-snip microscopy. A similar diagnostic performance range has been reported for the same field-based RDT in Burkina Faso among 400 children aged 3–9 years (sensitivity = 60% and specificity = 94%, when compared to skin-snip microscopy) [74] and for all ages in an ivermectin-naïve setting in Gabon (sensitivity = 52% and specificity = 95%, when compared to skin-snip microscopy for 4,257 participants aged ≥5 years) [75]. These estimates do not reach the WHO diagnostic Target Product Profile (TPP), which calls for very high specificity (≥99.8%) and more moderate sensitivity thresholds (≥60% for elimination mapping and ≥89% for stopping CDTI decisions) [76].
Secondly, REMO/REA nodule palpation remains helpful for delineating baseline endemicity, particularly in areas of moderate and high transmission, but is less sensitive in areas of low transmission or to indicate transmission declines than microscopy or serology [19]. For example, in Logo HZ, which never received CDTI, nodule prevalence in adult men remained in the meso- to hyperendemic range through 2017, whereas microfilarial prevalence in the same HAs (including the same villages) fell from 79.0% in 2010–2011 to 9.0% in 2021–2023. As adult worms survive for a decade or more [3,7] and the men examined in 2017 had median ages of 28–46 years, persistent nodules are compatible with worms acquired before the decline.
4.1 Limitations
We integrated programme histories, REMO/REA, study-based and community serological and skin-snip data, entomological observations and geospatial layers, enabling triangulation across designs and periods. This approach provides a comprehensive picture of the Kakoi–Koda focus but has several constraints. Firstly, several contributing studies were not designed to yield a population-representative sample of the focus. Most used pragmatic or study-specific enrolment criteria. For example, trial skin-snip screenings included participants aged ≥12 years, while case-control and epilepsy cohort studies used purposive sampling to investigate OAE rather than estimate population prevalence. Consequently, these studies may provide higher prevalence estimates than community-based surveys [55] and are interpreted as indicating where transmission may persist, rather than as estimates of population prevalence. Community serology surveys among children in Logo and Nyarambe HZs conducted in 2018 and 2021, respectively, provided complementary evidence of recent/ongoing O. volvulus transmission. We therefore emphasised patterns consistent across independent sources rather than individual study estimates.
Secondly, heterogeneity in study designs (trial screening, cross-sectional, case-control, cohort) and protocols (two versus four skin snips; microfilariae counted per snip or milligram of skin; differing age groups) limits precision and hampers direct comparisons of microfilarial intensity. The sensitivity of skin-snip microscopy increases with the number of snips and may miss light infections (e.g., in low-transmission or settings under CDTI), as suggested by modelling work [61]. Similarly, the Ov16 IgG4 RDT performed on whole blood has low and setting-dependent sensitivity [58,77]. To minimise bias, we restricted formal comparisons within study design groups, reported 95% CIs and ranges, and used exact tests (Fisher/Clopper-Pearson) when data were sparse. The trial-screening rounds also differed in sampling intensity and village composition. An individual-level, village-adjusted analysis of the trial-screening data has been published separately [22].
Thirdly, entomological findings are constrained by seasonal gaps, informal HLC procedures, limited PCR testing of S. vorax for O. volvulus larvae, and incomplete spatial coverage (notably across parts of Kakoi, Awo, Kuda/Muda and Lebu rivers), which limit the understanding of the capacity of these simuliid species to sustain O. volvulus transmission. Nevertheless, S. dentulosum samples were confirmed to indicate infectivity (O. volvulus DNA in heads) within the focus [18], and S. vorax has demonstrated competence for O. volvulus in laboratory settings [66] and can transmit Onchocerca dukei in cattle [18,78], indicating that both species remain epidemiologically relevant. Fourthly, tree-cover change was assessed from 30-metre imagery at a ≥70% canopy threshold. This measure captures the loss of forest blocks well, but only partially resolves the narrow riparian gallery forest most relevant to S. neavei.
Lastly, self-reported ivermectin intake in Kpanyi (very low among the moxidectin trial participants in 2021–2023) appears inconsistent with high CDTI coverage reports available in ESPEN for Nyarambe (80–84%) [21] and with the 2021 coverage among ivermectin-eligible children in Kpanyi (92%). While possible explanations include social desirability or reporting bias during screening and different sampling frames, this discrepancy warrants a targeted coverage verification survey.
4.2 Recommendations
Operationally, and in line with the WHO 2030 onchocerciasis elimination goal [1], risk-based surveillance should prioritise the Muda/Kuda and Lebu River basins and adjacent communities to determine whether CDTI should be initiated in Logo HZ and continued in the neighbouring HZs. Where ongoing transmission is verified, entomological monitoring should be considered to further characterise breeding sites, vector species, seasonal biting patterns, and infection/infectivity rates to guide interventions. Independent qualitative interviews with communities in Draju HA also identified the Kuda and Lebu lowland valleys as areas of highest current blackfly biting nuisance [31], independently highlighting these basins as priority areas for surveillance.
The assembled, standardised dataset accompanying this study may support transmission modelling to simulate prevalence changes in the focus [79]. In addition, blood-meal analysis could clarify host preferences of the current Simulium species found biting on humans and whether habitat change has altered human-vector contact, particularly in areas where flies may feed away from humans.
Although not population-representative, the case-control and cohort studies were informative for tracking epidemiological trends and, together with the recent community child surveys and second moxidectin skin-snip trial, helped identify areas where transmission may be reduced but not fully suppressed. Leveraging such local studies and other health programmes, for example, integrating anti-Ov16 RDTs or opportunistic skin-snip surveys into ongoing research or service platforms, may offer a pragmatic, interdisciplinary approach to strengthen NTD surveillance and optimise the limited logistical and financial resources available to tackle them, especially as external funding declines [80,81]. To maximise impact, datasets generated through such local studies and related health programmes should be shared openly to support planning and evaluation, as demonstrated in the depth of our analysis, which was possible only because previous data were accessible.
4.3 Conclusion
Epidemiological, entomological and geospatial evidence consistently indicate that O. volvulus infection indicators in the Kakoi–Koda focus have declined substantially since 2010, a pattern compatible with reduced transmission. The observations are compatible with reduced habitat suitability for S. neavei and possible shifts towards S. dentulosum and S. vorax. Programmatic effects (CDTI and small-scale trial treatments) may also have contributed to the observed declines when and where delivered. Whether the current vector species can maintain stable, endemic transmission remains uncertain, as current evidence suggests that any recent transmission may be limited and spatially fragmented. Targeted, integrated surveillance focused on the identified sub-basins should be prioritised before decisions on initiating, continuing or stopping CDTI and to support post-treatment surveillance. The standardised dataset assembled here provides a basis for future onchocerciasis transmission modelling. In operational terms, anti-Ov16 RDTs performed in the field broadly mirrored spatial patterns derived from skin-snip assessments, supporting cautious use as a complementary exploratory tool where the deployment of better diagnostics may not be feasible.
Supporting information
Supplementary dataset containing the epidemiological data used in the analyses for the Kakoi–Koda onchocerciasis focus.
Published trial-screening, entomological and programme data are cited in the manuscript instead.
(CSV)
Text A in S1 Appendix: ArcGIS README file for the interactive map of epidemiological, entomological and landscape data for the Kakoi–Koda onchocerciasis focus.
Text B in S1 Appendix: Anti-Ov16 ELISA and concurrent skin-snip microscopy shared by ESPEN (context surrounding the Kakoi–Koda focus). Fig A–H in S1 Appendix: Annual dense forest loss (2001–2024) by health zone and basin-level maps of dense forest in 2000 and dense forest loss (2001–2024) across the Kakoi–Koda focus (Awo basin; Muda tributaries of the Kuda basin; northern Lebu basin; northern Koda and Loda basins; north-western Kakoi basins; southern Koda and Loda basins and Mount Aboro). Table A in S1 Appendix: Nodule palpation prevalence by health zone and health area, Kakoi–Koda focus (2003–2017). Table B–D in S1 Appendix: detailed all-age and child anti-Ov16 serology and two-skin-snip results retained as contextual evidence. Table E in S1 Appendix: Dense forest cover in 2000 and cumulative loss (2001–2024) by health area in the five health zones of the Kakoi–Koda focus.
(DOCX)
25 May 2026
PNTD-D-26-00524
Epidemiological, vectorial and landscape changes in the context of declining Onchocerca volvulus transmission across the Kakoi-Koda focus, Ituri, Democratic Republic of the Congo
PLOS Neglected Tropical Diseases
Dear Dr. Amaral,
Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
Please submit your revised manuscript within by Jul 24 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
Please include the following items when submitting your revised manuscript:
* A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.
* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.
As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors.
We look forward to receiving your revised manuscript.
Kind regards,
Robert Adamu SHEY, Ph.D.
Guest Editor
PLOS Neglected Tropical Diseases
Eva Clark
Section Editor
PLOS Neglected Tropical Diseases
Shaden Kamhawi
co-Editor-in-Chief
PLOS Neglected Tropical Diseases
orcid.org/0000-0003-4304-636XX
Paul Brindley
co-Editor-in-Chief
PLOS Neglected Tropical Diseases
orcid.org/0000-0003-1765-0002
Journal Requirements:
1) We noticed that you used the phrase 'unpublished data' in the manuscript. We do not allow these references, as the PLOS data access policy requires that all data be either published with the manuscript or made available in a publicly accessible database. Please amend the supplementary material to include the referenced data or remove the references.
2) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines:
https://journals.plos.org/plosntds/s/figures
3) Some material included in your submission may be copyrighted. According to PLOS's copyright policy, authors who use figures or other material (e.g., graphics, clipart, maps) from another author or copyright holder must demonstrate or obtain permission to publish this material under the Creative Commons Attribution 4.0 International (CC BY 4.0) License used by PLOS journals. Please closely review the details of PLOS's copyright requirements here: PLOS Licenses and Copyright. If you need to request permissions from a copyright holder, you may use the PLOS Content Copyright Permission Form
Please respond directly to this email and provide any known details concerning your material's license terms and permissions required for reuse, even if you have not yet obtained copyright permissions or are unsure of your material's copyright compatibility. Once you have responded and addressed all other outstanding technical requirements, you may resubmit your manuscript within Editorial Manager.
Potential Copyright Issues:
i) Figures Figures 1, 2, 4, Appendix Figures B, C, D, E, F, G, and and H.. Please (a) provide a direct link to the base layer of the map (i.e., the country or region border shape) and ensure this is also included in the figure legend; and (b) provide a link to the terms of use / license information for the base layer image or shapefile. We cannot publish proprietary or copyrighted maps (e.g. Google Maps, Mapquest) and the terms of use for your map base layer must be compatible with our CC BY 4.0 license.
Note: if you created the map in a software program like R or ArcGIS, please locate and indicate the source of the basemap shapefile onto which data has been plotted.
If your map was obtained from a copyrighted source please amend the figure so that the base map used is from an openly available source. Alternatively, please provide explicit written permission from the copyright holder granting you the right to publish the material under our CC BY 4.0 license.
If you are unsure whether you can use a map or not, please do reach out and we will be able to help you. The following websites are good examples of where you can source open access or public domain maps:
* U.S. Geological Survey (USGS) - All maps are in the public domain. (http://www.usgs.gov)
* PlaniGlobe - All maps are published under a Creative Commons license so please cite u201cPlaniGlobe, http://www.planiglobe.com, CC BY 2.0u201d in the image credit after the caption. (http://www.planiglobe.com/?lang=enl)
* Natural Earth - All maps are public domain. (http://www.naturalearthdata.com/about/terms-of-use/).
4) Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published.
State what role the funders took in the study. If the funders had no role in your study, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.".
If you did not receive any funding for this study, please simply state: u201cThe authors received no specific funding for this work.u201d
Reviewers' Comments:
Reviewer's Responses to Questions
Key Review Criteria Required for Acceptance?
As you describe the new analyses required for acceptance, please consider the following:
Methods
-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?
-Is the study design appropriate to address the stated objectives?
-Is the population clearly described and appropriate for the hypothesis being tested?
-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?
-Were correct statistical analysis used to support conclusions?
-Are there concerns about ethical or regulatory requirements being met?
Reviewer #1: While the authors do a good job of avoiding inappropriate statistical comparisons, the net result is a very lengthy paper that is hard to read and extract the key findings. There aren't a lot of analyses in this paper, it is really a synthesis of existing data
Reviewer #2: This is a very well written paper where the authors combine multiple datasets to provide an assessment of changes in O. volvulus transmission in one district of DRC.
-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?
Yes, clear, but this should be better aligned with the abstract (missing an objective).
-Is the study design appropriate to address the stated objectives?
Yes
Methods clearly described. Only remark, as most of the infection prevalence data is generally difficult to obtain, maybe good to know where the original village-level data was obtained from (besides the scoping review data).
-Is the population clearly described and appropriate for the hypothesis being tested?
Difficult to assess if the eligibility criteria for sampling of population for moxidectin clinical trial are comparable to the nodule prev and serological studies.
-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?
Yes
-Were correct statistical analysis used to support conclusions?
Yes
-Are there concerns about ethical or regulatory requirements being met?
This study is using adult blackfly collection data obtained during a study in 2017, where Human Landing Catches were performed with ethical concerns for the catchers.
Reviewer #3: Major revision:
The key discovery is the transmission decline without CDTI, and the title does not highlight this. The authors should rephrase this title to make it more informative.
The background does not state the specific knowledge gap for Kakoi-Koda. Why do you conduct this study.
Line 31: In the methodology, “we synthesized” is too vague. State clearly that this is a scoping review
Line 45-46: The authors stated an overly confident causal statement: “Progressive deforestation…” change to “Progressive deforestation and canopy opening are consistent with a shift from crab-associated S. neavei to more open-habitat vectors, providing a plausible ecological mechanism."
Line 62-64: "This decline appears linked to..." is again too causal. Change to: "This decline appears to be associated with..."
Line 111-113 and line 118-126: The authors should move the detailed trial descriptions to a new subsection in methods (“Clinical trial contexts").
Line 96-103: The authors describe CDTI expansion in DRC, which is only tangentially relevant to the Kakoi-Koda focus. They should condense this part to one sentence.
In the last paragraph the authors present a descriptive aim (“we synthesize… and relate”), not testable hypothesis. The authors should reframe this last paragraph and state specifics hypotheses.
The authors should state in this section that most data sources are not population-representative and that results should be interpreted as descriptive of individuals sample, not necessarily in the general population. The authors should add a strong caveat like “due to the small number of skin-snip positive children, the sensitivity estimate is imprecise and should be interpreted with extreme caution.
Standardized HLC protocols have existed for decades. "Informal spot-checks" are non-reproducible and highly biased. Entomologic data should be removed or heavily caveated. Furthermore, opportunistic collections with tiny sample sizes cannot support quantitative conclusions about vector species or infection rates.
Line 601: Why were only 4/23 S. vorax tested? This needs justification. The prevalence estimate (1/4 = 25%) is statistically meaningless.
Considering the different studies for skin snip in this article, two vs four skin snips is a major issue for comparing intensities. The authors mention this in Discussion, but it should be stated as a limitation in methods and handled more rigorously (e.g., only compare prevalences, not intensities, between the two protocols).
Line 651-669: The paragraph with multiple percentages is indigestible. The authors should create supplementary table with all HA-level forest cover and loss percentages and summarize key patterns only in the text.
Comparison of prevalence estimates between 2009-2011 and 2021-2023 by looking at whether confidence intervals overlap is a weak descriptive approach. A mixed-effects logistic regression with village as random effect and survey period as fixed effect would quantify the decline while accounting for clustering.
The authors compare prevalence estimates between Table 4 (4 snips, mf/mg) and Table 5 (2 snips, mf/snip). This is invalid due to protocol heterogeneity.
**********
Results
-Does the analysis presented match the analysis plan?
-Are the results clearly and completely presented?
-Are the figures (Tables, Images) of sufficient quality for clarity?
Reviewer #1: The ArcGIS interactive map is a useful feature and a nice product to come from this paper.
I don't find Table 3 very useful because of the drastically different sampling approachs (e.g. case-control vs. cross-sectional vs. epilepsy cohort) and differing sample sizes (ranging from 4 - 163).
Reviewer #2: -Does the analysis presented match the analysis plan?
Sources of data described under Results section (lines 275-287 should rather be moved to Methods section)
-Are the results clearly and completely presented?
How were contradictory coverage data been dealt with (between CDTi cov data of different data sets and different age groups/target populations), as by Table 1 (should be explained in Methods section).
As mentioned, due to the merging of various datasets with different study populations, some data are not representative of actual prevalence of infection. This also mentioned by the authors (lines 405-409), but how to deal with this to correct for the expected overestimation of seroprevalence?
- Table 1, nodule prevalence surveys likely only performed among cases with epilepsy in the epilepsy cohort. If so, these nodule data are not representative for the full population. Difficult to assess as no reference to original epilepsy cohort dataset. If so, then the only representative dataset is the 2003 REMO dataset, which is already 20+ years outdated. How dealt with?
The description is complete for the various sections representing Tables 3-5, but as there are many variations across districts and diagnostics, a clear visualisation of these trends per district would be very much appreciated.
Likewise, an easy visualisation (besides the online map) guiding the text concerning crab collections and Simulium breeding sites or species, (for instance with a stagged bar chart) would be welcome to guide the reader through the text.
The dense forest cover loss seems a stand-alone analysis, as no associative or causal analyses were performed between infection declines and forest losses. This is a lost chance. Also the spatial boundaries of the forest cover map has not been overlayed with infection prevalence. Fig 2 and Fig 4 are no separate images whereas it would be interesting to see where (over time) high infection rates would be found, having the forest cover loss directly underneath for clear comparison.
-Are the figures (Tables, Images) of sufficient quality for clarity?
yes
Reviewer #3: Minor revisions:
**********
Conclusions
-Are the conclusions supported by the data presented?
-Are the limitations of analysis clearly described?
-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?
-Is public health relevance addressed?
Reviewer #1: (No Response)
Reviewer #2: -Are the conclusions supported by the data presented?
Yes, as mentioned a causal/associative relationship between canopy and forest cover with infection would help to substantiate these conclusions
-Are the limitations of analysis clearly described?
Yes
-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?
Lines 733-735, the authors refer several times to modelling studies, but why not compare your data with actual trends using field data? Think of publications from Burkina Faso, Ghana, Togo, Guinea-Bissau?
-Is public health relevance addressed?
yes, relevant study and strong that various ways of measuring transmission are taken into account. This study shows that areas of Muda/Kuda and Lebu River basins of DRC should be prioritised for onchocerciasis interventions (Kakoi-Koda focus). Interesting enough, it seems that – all data combined – the overall/global results are still not very different than the map presented in Fig. 2. In absence of an updated, and integrated map, this a actual lack in addressing the public health relevance.
Reviewer #3: Major revision:
Line 764-765: The hypothesis “sociopolitical instability and immigration of relatively wealthier households who are less engaged in…” is not supported by any data presented in the manuscript. The authors should remove it.
Line 781-785: "The marked onchocerciasis prevalence decline in Logo... points towards a substantial role for ecological drivers…" This is correlation, not causation. The authors do not have no historical entomological data on S. neavei abundance before deforestation. They should revise causal language.
The authors claim the RDT is useful and supports its use. However, with 43% sensitivity, the RDT would miss more than half of truly infected children. The authors should revise this conclusion about anti-Ov16 RDTs.
**********
Editorial and Data Presentation Modifications?
Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.
Reviewer #1: The article is written very clearly - the prose is excellent - it is just too long and lacks cohesion.
Reviewer #2: In order to accept this manuscript, the authors will need to revise their manuscript. Recommendation is minor revision.
- Abstract “We collated anti-Ov16 serological data from epilepsy-related studies”, study population may be different (were OV16 samples collected
- Abstract, unclear aim of the study
- Introduction: ref 2 doesn’t fit the quote (99% oncho in Africa, but ref is about GBD 2016 epilepsy)
- Ref 3 is not befit for quote in line 87, rather use studies on vector control from the OCP area.
- Lines 90-91, I think ref by Chesnais et al would be more appropriate : https://pubmed.ncbi.nlm.nih.gov/30268645/
- Line 117, CDTi for LF, this can only be ivermectin if Loa loa non-endemic, so LF Tx does not per se means it helps against O. volvulus. Explain more sharply
- S1 Database does not seem to have entomological data. There are some mistakes in the LAT/LON. Analyses actually only based on about 2000 records (age and sex stratified)?
Reviewer #3: Minor revision
**********
Summary and General Comments
Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.
Reviewer #1: This study seeks to synthesize data on onchocerciasis (both in humans and vectors) in the Kakoi-Koda focus in DRC. While such an effort is laudable and the authors clearly did a lot of work to compile all the information, it is difficult for the reader to digest as presented. The data include a mix of geographic locations, time points, sampling strategies and diagnostic tests, which makes it difficult (and inappropriate) to combine and compare statistically. The authors refrain from statistical comparisons when the sampling methodology or geographic scale are different; however, the net result is the paper lacks cohesion. It is hard to see the "forest through the trees" with the density of informaton presented, much of which is not directly comparable. The authors' main thesis: that the prevalence is declining over time, likely due to deforestation, doesn't come through clearly from the way the data are presented (and the sheer length of the paper). I strongly encourage the authors to rethink how the informaton is presented and to remove any data that don't enable a comparison over time (e.g. any sites with single time point data) - or at least move this to a supplemental file. Focusing in on the few datasets and locations that tell the story will greatly strengthen this article.
Reviewer #2: Overall, a nice and well-written manuscript with an in-depth analysis of one region in DRC. This is useful for advancing district-level onchocerciasis interventions. However, there is a strong recommendation to more clearly link forest cover and canopy data with infection. Now, these associations seem to be more of a speculation. Also, the authors use a lot of detailed tables, which are also informative, but I would strongly recommend to visualise the merged data – as visualations is more intuitive for many readers (the main figures are now the old REMO map, and the landcover map, which is not associated with infection occurrence.
Reviewer #3: As part of the peer review process, I have reviewed the manuscript entitled "Epidemiological, vectorial and landscape changes in the context of declining Onchocerca volvulus transmission across the Kakoi-Koda focus, Ituri, Democratic Republic of the Congo" (Manuscript PNTD-D-26-00524). It is a synthesis work, bringing together epidemiological, entomological, programme-related and geospatial data from a historical onchocerciasis focus in the DRC over two decades. The triangulation of evidence and the public release of data are notable strengths.
However, the manuscript has several methodological and stylistic weaknesses that, in my opinion, prevent it from being accepted in its current form. I therefore recommend major revisions.
**********
PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.
If you choose “no”, your identity will remain anonymous but your review may still be made public.
Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.
Reviewer #1: No
Reviewer #2: No
Reviewer #3: No
[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]
Figure resubmission:
Reproducibility:
To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols
Submitted filename: Revision_Comment_Plos.docx
Submitted filename: Review report.docx
4 Aug 2026
Submitted filename: IturiResponse to Reviewers.docx
17 Aug 2026
Dear Dr Amaral,
We are pleased to inform you that your manuscript 'Declining Onchocerca volvulus transmission despite limited ivermectin delivery in the Kakoi–Koda focus, Ituri, Democratic Republic of the Congo: an epidemiological, entomological and landscape evidence synthesis' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.
Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.
Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.
IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.
Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.
Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.
Best regards,
Robert Adamu SHEY, Ph.D.
Guest Editor
PLOS Neglected Tropical Diseases
Eva Clark
Section Editor
PLOS Neglected Tropical Diseases
Shaden Kamhawi
co-Editor-in-Chief
PLOS Neglected Tropical Diseases
orcid.org/0000-0003-4304-636XX
Paul Brindley
co-Editor-in-Chief
PLOS Neglected Tropical Diseases
orcid.org/0000-0003-1765-0002
***********************************************************
p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; line-height: 16.0px; font: 14.0px Arial; color: #323333; -webkit-text-stroke: #323333}span.s1 {font-kerning: none
Dear Dr Amaral,
We are delighted to inform you that your manuscript, "Declining Onchocerca volvulus transmission despite limited ivermectin delivery in the Kakoi–Koda focus, Ituri, Democratic Republic of the Congo: an epidemiological, entomological and landscape evidence synthesis," has been formally accepted for publication in PLOS Neglected Tropical Diseases.
We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.
The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.
Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.
For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.
Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.
Best regards,
Shaden Kamhawi
co-Editor-in-Chief
PLOS Neglected Tropical Diseases
Paul Brindley
co-Editor-in-Chief
PLOS Neglected Tropical Diseases